Trial Profile

Phase I trial of 57-57 (paquinimod) in patients with systemic lupus erythematosus.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paquinimod (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions

Most Recent Events

30 Nov 2011 Results published in Arthritis and Rheumatism.
17 Sep 2010 New trial record
16 Sep 2010 An update on this trial will be presented at the UBS Global Life Sciences Conference, September 2010, according to an Active Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com